Keywords: biota, quarterly, relenza, royalties, grow, 16m, australian

Biota's quarterly Relenza royalties grow to A$16M

Article | 07 May 2007

Australian drug development firm Biota Holdings says that it has received written notification from UK-based pharmaceutical major GlaxoSmithKline indicating that, ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Companies

GlaxoSmithKline

GSK

Go to company listing

Related Drugs

Relenza

Zanamivir

Go to drug listing